Drug Database
LA

lamivudine + zidovudine + abacavir (abacavir + Combivir / Combivir + abacavir / Trizivir)

✓ Approved

Shire · · 小分子

什么是 lamivudine + zidovudine + abacavir?

lamivudine + zidovudine + abacavir 是一种小分子,由Shire研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名abacavir + Combivir, Combivir + abacavir, Trizivir
公司Shire
药物类别小分子
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

lamivudine + zidovudine + abacavir 作用于 1 个分子靶点:

gag-pol, HIV-1 (gag-pol)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

lamivudine + zidovudine + abacavir 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsAcquired immunodeficiency syndrome✓ Approved

相关研究文献

PubMedOphthalmic plastic and reconstructive surgery2026-11-19

Ptosis in Long-Term HIV Patients: A Clinical Marker of Mitochondrial Dysfunction and Surgical Management.

Matagrin Benjamin B, Callet Marie M, Jacomet Pierre-Vincent PV, Azria Sophie S et al.

Since the introduction of Highly Active Antiretroviral Therapy (HAART), human immunodeficiency virus (HIV) infection has transitioned from a fatal to a manageable chronic condition. However, long-term exposure to first-generation nucleoside reverse transcriptase inhibitors (NRTIs), including zidovudine, stavudine, didanosine, and zalcitabine, is associated with significant mitochondrial toxicity. Mitochondria-dependent muscles, such as the levator palpebrae superioris, may be particularly vulnerable. Case reports have suggested a link between NRTI exposure and ptosis, but this relationship has not been the subject of a detailed systematic evaluation. This study investigated ptosis as a potential clinical marker of acquired mitochondrial dysfunction in patients with long-term HIV exposure to NRTIs and evaluated surgical outcomes. This monocentric retrospective study included 63 HIV-infected patients (109 eyelids) treated for ptosis between 2012 and 2024 at the Fondation Adolphe de Rothschild Hospital. Clinical and surgical data were extracted, including levator function, palpebral fissure height, margin reflex distance 1, ophthalmological findings (diplopia, ophthalmoplegia, and pigmentary retinopathy), neurological comorbidities, and HIV treatment history. Levator muscle biopsies were performed during surgery when indicated, with subsequent histological and molecular analyses to assess the mitochondrial pathology. Patients were grouped based on levator function, and the association between cumulative duration of antiretroviral therapy and neurological/ophthalmological findings was assessed using a data-driven cutoff analysis scanning all possible duration thresholds. The cohort had a mean age of 68.3 years; 76% underwent ptosis surgery, most commonly anterior levator resection (79%). Most patients (67%) were diagnosed with HIV infection before 2000, with a mean treatment duration of 32.5 years. Levator function was limited (<8 mm) in 18% of cases. Diplopia or ophthalmoplegia and pigmentary retinopathy occurred in 32% and 13% of the eyelids, respectively. These manifestations were strongly associated with limited levator function (diplopia, 80% vs. 21%, p < 0.001; retinopathy, 50% vs. 4.5%, p < 0.001). Mixed axonal neuropathy and encephalopathy were also significantly more common in the limited function group. No significant association was found between cumulative antiretroviral therapy duration and any neurological or ophthalmological finding, including after testing all possible duration cutoffs. The overall surgical revision rate was 17%, which was higher in the patients with limited levator function (27.8%) and pigmentary retinopathy (40%). Only one muscle biopsy revealed mitochondrial myopathy (ragged-red fibers and cytochrome c oxidase-negative fibers). Genetic analysis of this patient showed focal deletions, supporting an acquired toxic origin. This study represents the largest reported series investigating ptosis in patients with HIV and its potential mitochondrial origin. The data support a strong correlation between limited levator function and ophthalmoneurological findings, consistent with mitochondrial dysfunction. The absence of large-scale mitochondrial DNA deletions and the late onset of symptoms argue against congenital syndromes, favoring a model of NRTI-induced acquired mitochondriopathy. The observed phenotype aligns with a Kearns-Sayre syndrome-like presentation. These findings suggest parallel conditions, such as myasthenia gravis, in which ptosis may constitute an early manifestation of broader disease involvement. While the use of first-generation NRTIs has declined in high-resource settings, continued vigilance is warranted in low-resource countries, where these agents remain in circulation. Ptosis may serve as an early and accessible clinical marker for antiretroviral-induced mitochondrial toxicity. Our findings reinforce the importance of long-term vigilance for neuromuscular signs in patients with HIV, especially those exposed to early-generation NRTIs. Future multicenter studies are needed to confirm these observations and refine diagnostic and surgical strategies.

PMID 43056747
阅读全文 →
PubMedMalawi medical journal : the journal of Medical Association of Malawi2026-11-18

The First Extensively Drug-Resistant (XDR) Tuberculosis Patient Diagnosed in Malawi - a Case Report.

Talama George C GC, Kadyeremwana Bright B, Kwenje Charles C, Mtalika Sosten S et al.

We report the first case of extensively drug-resistant (XDR) TB diagnosed in Malawi. A 43-year-old female living with HIV, on tenofovir-lamivudine-dolutegravir antiretroviral therapy, with long-term viral suppression, accumulated resistance to rifampicin, levofloxacin, and linezolid on successive TB treatment regimens between 2018 and 2024, qualifying as XDR-TB. Throughout treatment as an outpatient, she regularly missed TB visits and reported poor TB drug adherence, mainly related to alcohol abuse and inconsistent availability of funds for transport. After XDR-TB diagnosis, the patient, guardians, treatment providers, and health facility leadership agreed to management as an inpatient in August 2024, when she started an 18-month regimen of bedaquiline-delamanid-cycloserine-clofazimine-pyrazinamide, with good treatment outcome. The emergence of XDR-TB in Malawi calls for further scale-up of TB resistance testing and structured approaches to improving drug adherence among drug-resistant TB patients.

PMID 43047292
阅读全文 →
PubMedJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2026-11-18

Simultaneous quantification of bictegravir and four other antiretroviral drugs in human plasma and cerebrospinal fluid by LC-MS/MS: method validation and clinical application.

Bai Haihong H, Fang Yuan Y, Wang Zihe Z, Zhang Yang Y et al.

Despite transforming human immunodeficiency virus (HIV) into a manageable chronic condition, combination antiretroviral therapy (cART) is still challenged by complications, such as drug-drug interactions, suboptimal adherence, and HIV-associated neurocognitive disorders. To optimize treatment, accurate quantification of antiretroviral concentrations in both plasma and cerebrospinal fluid (CSF) is essential. Therefore, in this research, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for simultaneous quantification of five antiretroviral drugs: bictegravir (BIC), emtricitabine (FTC), lamivudine (3TC), dolutegravir (DTG), and efavirenz (EFV) in human plasma and CSF. Following protein precipitation with acetonitrile containing isotope-labeled internal standards, analytes were separated on a C18 column via gradient elution at 1.0 mL/min. The result demonstrated that all the five antiretroviral drugs exhibited excellent linearity in the range of 0.01-5.0 μg/mL for BIC, FTC, 3TC, and DTG, and 0.1-5.0 μg/mL for EFV in both matrices. The selectivity, lower limit of quantification, matrix effect, precision, accuracy, extraction recovery, and stability all satisfied the requirements of the guidelines. Finally, the method was successfully applied for concentration monitoring of the five antiretroviral drugs in plasma and CSF samples from HIV-infected patients, demonstrating its utility for therapeutic drug monitoring and neuropharmacokinetic studies. This harmonized approach enables high-throughput, matrix-independent quantification, addressing a critical gap in clinical research and paving the way for more effective, individualized treatment strategies.

PMID 43050916
阅读全文 →
PubMedAnalytical chemistry2026-11-18

In Situ Time-Weighted Average Monitoring of 11 Antiviral Drugs in Natural Waters Using Diffusive Gradients in Thin-Films with Graphitized Carbon Black and Mixed-Mode Resin Binding Gels.

Fang Zhou Z, Huang Kefei K, Zhang Hao H, Jones Kevin C KC et al.

The widespread occurrence of antiviral drugs in aquatic systems has raised concerns on their potential ecological risks, necessitating reliable monitoring techniques. This study introduces the first application of the diffusive gradients in thin-films (DGT) technique for the in situ measurement of 11 commonly used antiviral drugs from six therapeutic categories. Two complementary DGT configurations were developed, employing graphitized carbon black (ENVI-CARB) and a mixed-mode resin (MCX + HLB at a 6:4 mass ratio) embedded in agarose as the binding phases. Diffusion coefficients of all target compounds in the diffusive gel were determined for the first time using a diffusion cell, and stable elution efficiencies were obtained with acetonitrile/formic acid for ENVI-CARB and acetonitrile/ammonia for MCX + HLB. Both DGT devices performed robustly across wide environmental gradients: pH 3.16-9.74, ionic strength 0.1-500 mmol L-1 and dissolved organic matter up to 20 mg L-1. The total binding capacities exceeded 230 μg per disc, supporting deployments over several months in natural waters. Laboratory evaluations of diffusive layer thickness (0.515-2.015 mm), deployment time (10-168 h), storage stability (≥148 days) and competitive adsorption confirmed the reliability of the method. Field deployments at five river sites in Nanjing, China, during a 14 day period detected ribavirin (9-29 ng L-1) and lamivudine (12-29 ng L-1) as the predominant antivirals. The DGT-derived time-weighted average concentrations closely matched those from repeated grab sampling while effectively capturing episodic pollution events that individual grab samples missed. The developed DGT samplers thus provide a robust, cost-effective and sensitive tool for source tracking and long-term monitoring of antiviral drugs, overcoming the inherent limitations of conventional grab sampling in dynamic aquatic environments.

PMID 43046361
阅读全文 →
PubMedResearch connections2026-11-15

Maternal and fetal outcomes in mice following exposure to dolutegravir alone or in combination with lamivudine or tenofovir disoproxil fumarate/emtricitabine.

Mohan Haneesha H, Nguyen Jessica J, Yee Audrey A, Laurette Evelyn Yukino EY et al.

Dolutegravir (DTG)-based regimens are widely used in HIV treatment, including during pregnancy, but the contribution of the nucleoside reverse transcriptase inhibitor (NRTI) backbone on maternal and foetal outcomes remains unclear. We examined this in a large mouse fetotoxicity study. Pregnant C57BL/6J mice were randomized to control (water), DTG-alone, DTG+ Lamivudine (3TC), or DTG+tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), and treated daily from GD0.5 to GD15.5 at clinically relevant doses. Maternal weight gain, litter size, foetal and placental weights, and foetal anomalies were assessed. Kruskal-Wallis and generalized -linear models were used for statistical comparisons. Four hundred seventy two litters were evaluated (115 control, 106 DTG, 101 DTG + 3TC, 150 DTG + TDF/FTC). Foetal viability and resorptions were similar across groups. Maternal weight gain was significantly higher in the DTG and DTG + 3TC groups compared to control, but lower in DTG + TDF/FTC. Foetal and placental weights were significantly lower in DTG + TDF/FTC and DTG + 3TC groups versus controls, but not in DTG-alone. Nine neural tube defects occurred only in the DTG-exposed groups, most frequently in DTG + TDF/FTC. DTG was associated with higher rates of several foetal anomalies compared to controls, whether administered alone or in combination with NRTIs. Compared to DTG + TDF/FTC, cranial swelling and oedema rates were lower in DTG + 3TC, and tail and limb defects were higher in the DTG-alone group. TDF inclusion was associated with absence of DTG-associated excess maternal weight gain. NRTI inclusion was associated with lower foetal and placental weights. DTG-associated maternal and foetal outcomes in mice vary by NRTI backbone, highlighting the importance of considering each regimen component, and need for ongoing safety evaluation in pregnancy.

PMID 43032811
阅读全文 →
PubMedCureus2026-11-15

Disseminated Cutaneous Tophaceous Gout in a Man With Advanced HIV Disease.

de Jager Ruan S RS, Iyer Caitlin C, Kannenberg Susanna M SM

Cutaneous tophi typically develop at periarticular sites in patients with longstanding gout. Widespread dermal deposition of monosodium urate beyond these sites is uncommon and is not recognized as a manifestation of human immunodeficiency virus (HIV) infection. We report a 54-year-old man with advanced HIV disease who presented with a ten-year history of progressively enlarging nodules on both lower limbs. HIV had been diagnosed in 2019, and he had been virologically suppressed on tenofovir disoproxil fumarate, lamivudine, and dolutegravir since 2020, although his CD4 count remained 34 cells/µL. The lesions were asymptomatic and had not previously been investigated. Examination showed numerous firm, hyperpigmented papules and nodules across both lower limbs together with bilateral olecranon tophi. Serum urate was 0.61 mmol/L, renal function was mildly reduced, and body mass index was 41 kg/m². Punch biopsy demonstrated dermal deposits of amorphous, feathery eosinophilic material bordered by a granulomatous infiltrate, and stains for mycobacteria and fungi were negative. No tissue cultures were obtained; disseminated cutaneous tophaceous gout was diagnosed by clinicopathologic correlation rather than crystal identification. Allopurinol was restarted with dose escalation and colchicine prophylaxis. At six months, the serum urate had fallen to 0.40 mmol/L, within the laboratory reference range but above the target for tophaceous gout, and the tophi had not regressed. This case shows how asymptomatic skin disease can go uninvestigated for years in a patient with a demanding chronic illness. We report the two conditions as coexisting and do not suggest that HIV caused the cutaneous tophi.

PMID 43034805
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多lamivudine + zidovudine + abacavir